Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

8.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.3K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.2K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.2K
Drug Discovery: Overview01:26

Drug Discovery: Overview

9.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
9.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alternative antigen to defuse SARS-CoV-2 delta variant and its ensuing evolutionary lineage.

Expert opinion on therapeutic targets·2021
Same author

Artificial Intelligence Set to Reverse Engineer Drug Targeting in the Cell.

ACS pharmacology & translational science·2021
Same author

Molecular Biology Clues Portray SARS-CoV-2 as a Gain-of-Function Laboratory Manipulation of Bat CoV RaTG13.

ACS medicinal chemistry letters·2021
Same author

Artificial Intelligence Teaches Drugs to Target Proteins by Tackling the Induced Folding Problem.

Molecular pharmaceutics·2020
Same author

Artificial Intelligence Steering Molecular Therapy in the Absence of Information on Target Structure and Regulation.

Journal of chemical information and modeling·2019
Same author

Drug-based cancer therapy to overcome immune resistance by steering tumor evolution.

Expert opinion on drug discovery·2018

Related Experiment Video

Updated: Oct 28, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.1K

Artificial Intelligence Deconstructs Drug Targeting In Vivo by Leveraging a Transformer Platform.

Ariel Fernández1,2

  • 1Daruma Institute for AI in Pharmaceutical Research, AF Innovation Pharma Consultancy, GmbH, 4000 Pemberton Court, Winston-Salem, North Carolina 27106, United States.

ACS Medicinal Chemistry Letters
|July 16, 2021
PubMed
Summary

Transformer technologies may soon allow computational modeling of how drugs affect protein folding in vivo. This advance could improve structure-based drug design by better predicting therapeutic agent behavior within cells.

More Related Videos

A Swin Transformer-Based Model for Thyroid Nodule Detection in Ultrasound Images
04:23

A Swin Transformer-Based Model for Thyroid Nodule Detection in Ultrasound Images

Published on: April 21, 2023

2.1K
Swin-PSAxialNet: An Efficient Multi-Organ Segmentation Technique
04:48

Swin-PSAxialNet: An Efficient Multi-Organ Segmentation Technique

Published on: July 5, 2024

589

Related Experiment Videos

Last Updated: Oct 28, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.1K
A Swin Transformer-Based Model for Thyroid Nodule Detection in Ultrasound Images
04:23

A Swin Transformer-Based Model for Thyroid Nodule Detection in Ultrasound Images

Published on: April 21, 2023

2.1K
Swin-PSAxialNet: An Efficient Multi-Organ Segmentation Technique
04:48

Swin-PSAxialNet: An Efficient Multi-Organ Segmentation Technique

Published on: July 5, 2024

589

Area of Science:

  • Computational chemistry
  • Structural biology
  • Drug discovery

Background:

  • Structure-based drug design requires evaluating therapeutic agents in a cellular context.
  • Controlling target structure in vivo for computational modeling remains a significant challenge.

Purpose of the Study:

  • To explore how emerging transformer technologies can address the limitations in modeling in vivo protein behavior.
  • To investigate the potential of deconstructing in vivo cooperativity in drug-induced protein folding.

Main Methods:

  • Utilizing transformer technologies for computational analysis.
  • Deconstructing in vivo cooperativity mechanisms.
  • Analyzing drug-induced protein folding pathways.

Main Results:

  • Transformer technologies show promise in analyzing complex in vivo biological processes.
  • A potential framework for deconstructing in vivo cooperativity in protein folding is proposed.

Conclusions:

  • Advancements in transformer technology may overcome current limitations in computational drug design.
  • This approach could lead to more accurate prediction of drug efficacy and behavior in cellular environments.